The role of the endogenous cannabinoid system in drug addiction.
This review aims to present the more recent knowledge on the role of the endocannabinoid system in drug addiction. For a long time, dopamine has been consistently associated with the reinforcing effects of most drugs of abuse but, recently, pharmacological evidence points to the possibility that pharmacological management of the endocannabinoid system might not only block the direct reinforcing effect of cannabis, opioids, nicotine and ethanol, but also prevent the relapse to various drugs of abuse including opioids, cocaine, nicotine, alcohol and amphetamine. Preclinical and clinical studies suggest that the manipulation of the endocannabinoid system through the CB(1) receptor antagonist SR-141716A (rimonabant) might constitute a new therapeutical strategy for treating addiction across different classes of abused drugs.
DBSF and Neuroscience Center, University of Insubria, Busto Arsizio, Italy. daniela.parolaro@uninsubria.it
D
D
Parolaro
T
T
Rubino
D000437:Alcoholism / Q000503:physiopathology / Q000523:psychology; D000818:Animals; D063385:Cannabinoid Receptor Modulators / Q000502:physiology*; D000697:Central Nervous System Stimulants; D006801:Humans; D009293:Opioid-Related Disorders / Q000503:physiopathology / Q000523:psychology; D019966:Substance-Related Disorders / Q000503:physiopathology* / Q000523:psychology; D014029:Tobacco Use Disorder / Q000503:physiopathology / Q000523:psychology
D063385:Cannabinoid Receptor Modulators; D000697:Central Nervous System Stimulants